MoonLake Immunotherapeutics (MLTX) News Today → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free MLTX Stock Alerts $42.41 -0.02 (-0.05%) (As of 11:15 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives "Buy" Rating from HC Wainwrightamericanbankingnews.com - April 24 at 4:44 AMMoonLake Immunotherapeutics: A Promising Outlook with Sonelokimab’s Potential in the HS Marketmarkets.businessinsider.com - April 23 at 3:57 PMMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 23 at 8:20 AMBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for Sonelokimabmarkets.businessinsider.com - April 23 at 12:18 AMFederated Hermes Inc. Trims Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)marketbeat.com - April 19 at 8:45 AMMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 12 at 2:17 AMMoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel Optimismmarkets.businessinsider.com - April 11 at 8:37 PMHC Wainwright Reaffirms "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)marketbeat.com - April 11 at 8:26 AMMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditionsbusinesswire.com - April 10 at 7:00 AMMoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditionsglobenewswire.com - April 10 at 7:00 AMGoldman starts MoonLake at neutral, cites lead drug potentialmsn.com - April 2 at 3:20 PMThe Goldman Sachs Group Initiates Coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX)marketbeat.com - April 2 at 8:23 AMMLTX Aug 2024 80.000 callfinance.yahoo.com - March 25 at 7:23 AMMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.1%marketbeat.com - March 20 at 3:55 PMMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - March 18 at 2:24 AMWalleye Capital LLC Purchases New Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX)marketbeat.com - March 16 at 4:53 AMMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 4.8%marketbeat.com - March 15 at 1:47 PMMLTX May 2024 60.000 callfinance.yahoo.com - March 12 at 8:04 AMMLTX Apr 2024 40.000 putfinance.yahoo.com - March 12 at 2:07 AMMoonLake Immunotherapeutics Shares Rise Premarket After Pipeline Updatemarketwatch.com - March 11 at 4:06 PMWhy Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?msn.com - March 11 at 4:06 PMPolar Capital Holdings Plc Sells 676,377 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)marketbeat.com - March 11 at 1:50 PMMoonLake price target raised to $100 from $75 at H.C. Wainwrightrealmoney.thestreet.com - March 11 at 10:18 AMMoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Dayglobenewswire.com - March 10 at 12:00 PMQ1 2024 Earnings Estimate for MoonLake Immunotherapeutics (NASDAQ:MLTX) Issued By HC Wainwrightmarketbeat.com - March 7 at 6:40 AMHC Wainwright Weighs in on MoonLake Immunotherapeutics' Q1 2025 Earnings (NASDAQ:MLTX)marketbeat.com - March 6 at 8:13 AMBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical and Regulatory Advancesmarkets.businessinsider.com - March 4 at 2:57 PMAdage Capital Partners GP L.L.C. Has $111.30 Million Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)marketbeat.com - March 4 at 10:37 AMMoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by HC Wainwrightmarketbeat.com - March 4 at 8:24 AMMoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024globenewswire.com - March 4 at 8:00 AMMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 7.6% on Earnings Beatmarketbeat.com - March 3 at 1:03 AMMoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPSmarketbeat.com - March 1 at 1:57 PMMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 7.6% Following Strong Earningsmarketbeat.com - March 1 at 10:15 AMInsider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)finance.yahoo.com - March 1 at 1:10 AMAnalysts Offer Predictions for MoonLake Immunotherapeutics' FY2028 Earnings (NASDAQ:MLTX)marketbeat.com - February 29 at 9:45 AMMoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10globenewswire.com - February 29 at 8:00 AM56,000 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by Soros Fund Management LLCmarketbeat.com - February 28 at 4:55 PMMoonLake Immunotherapeutics: A Promising Buy on Streamlined Clinical Progress and Regulatory Synergymarkets.businessinsider.com - February 28 at 9:06 AMMoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)globenewswire.com - February 26 at 8:00 AMMoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3seekingalpha.com - February 25 at 8:59 PM39,800 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Bought by Swiss National Bankmarketbeat.com - February 25 at 4:03 AMFmr LLC Buys 19,508 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)marketbeat.com - February 24 at 6:02 AMMoonLake Stock (NASDAQ:MLTX) Dividends: History, Yield and Datesbenzinga.com - February 22 at 11:37 PMMoonLake Stock (NASDAQ:MLTX), Short Interest Reportbenzinga.com - February 22 at 11:37 PMCHI Advisors LLC Invests $3.42 Million in MoonLake Immunotherapeutics (NASDAQ:MLTX)marketbeat.com - February 22 at 1:39 PMInsider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeuticsfinance.yahoo.com - February 21 at 5:21 AMMLTX Mar 2024 80.000 callfinance.yahoo.com - February 17 at 1:08 AMMoonLake Immunotherapeutics (NASDAQ:MLTX) Insider Kristian Reich Sells 10,000 Sharesmarketbeat.com - February 16 at 6:54 PMMaven Securities LTD Invests $570,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX)marketbeat.com - February 16 at 8:21 AMMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives New Coverage from Analysts at Wolfe Researchmarketbeat.com - February 15 at 7:24 AM Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. MLTX Media Mentions By Week MLTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼0.640.44▲Average Medical News Sentiment MLTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼63▲MLTX Articles Average Week Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ACAD News Today MOR News Today INDV News Today HCM News Today ARWR News Today JANX News Today IDYA News Today EVO News Today SMMT News Today FOLD News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyWill this $2 AI stock double overnight?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
